Document Detail


Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
MedLine Citation:
PMID:  16618816     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The cardiovascular safety of cyclooxygenase (COX)-2-selective nonsteroidal antiinflammatory drugs (NSAIDs) has come under scrutiny after the withdrawal of rofecoxib and halting of the Adenoma Prevention with Celecoxib trial. Whether the newer second-generation COX-2 inhibitors (etoricoxib, valdecoxib) also increase the cardiovascular risk is unknown. METHODS AND RESULTS: We performed a nested case-control study in a cohort of 486,378 persons registered within the United Kingdom General Practice Research Database with at least 1 prescription of an NSAID between June 1, 2000, and October 31, 2004. A total of 3643 cases with acute myocardial infarction (AMI) were matched to 13,918 controls on age, sex, year of cohort entry, and general practice. Rate ratios (RRs) of AMI associated with use of COX-2-selective and -nonselective NSAIDs were calculated. Current use of etoricoxib was associated with a 2.09-fold (95% confidence interval [CI], 1.10 to 3.97) risk of AMI compared with no use of NSAIDs during the prior year. Current use of rofecoxib (RR=1.29; 95% CI, 1.02 to 1.63), celecoxib (RR=1.56; 95% CI, 1.22 to 2.00), and diclofenac (RR=1.37; 95% CI, 1.17 to 1.59) also significantly increased the AMI risk. For current use of valdecoxib, the RR was 4.60 (95% CI, 0.61 to 34.51). RRs appeared to increase with higher daily doses of COX-2 inhibitors and were also increased in patients without major cardiovascular risk factors. CONCLUSIONS: Our study supports the hypothesis that the elevated risk of AMI is a class effect of COX-2 inhibitors. The increase in risk appears to be dose dependent, but further data are needed to verify this observation.
Authors:
Frank Andersohn; Samy Suissa; Edeltraut Garbe
Related Documents :
16170756 - The rate of viral rebound after attainment of an hiv load <50 copies/ml according to sp...
19724046 - Combined corticosteroid and antiviral treatment for bell palsy: a systematic review and...
20091626 - Medical treatments for incomplete miscarriage (less than 24 weeks).
18425916 - Chinese herbal medicine for primary dysmenorrhoea.
11253236 - Gender differences in patients undergoing coronary artery bypass surgery, from a mandat...
15925416 - Fasting insulin concentrations and coronary heart disease incidence in france and north...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-04-17
Journal Detail:
Title:  Circulation     Volume:  113     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-04-25     Completed Date:  2006-05-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1950-7     Citation Subset:  AIM; IM    
Affiliation:
Department of Clinical Pharmacology, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
Case-Control Studies
Cyclooxygenase 2 Inhibitors / adverse effects*
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Myocardial Infarction / chemically induced*
Risk
Risk Factors
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase 2 Inhibitors
Comments/Corrections
Comment In:
Nat Clin Pract Cardiovasc Med. 2006 Oct;3(10):532-3   [PMID:  16990835 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Direct in vivo monitoring of sarcoplasmic reticulum Ca2+ and cytosolic cAMP dynamics in mouse skelet...
Next Document:  Myocardial structure and function differ in systolic and diastolic heart failure.